Vascular Biogenics Ltd. - Ordinary Shares (VBLT) News
Filter VBLT News Items
VBLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VBLT News Highlights
- VBLT's 30 day story count now stands at 3.
- Over the past 12 days, the trend for VBLT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VBLT are SP and VC.
Latest VBLT News From Around the Web
Below are the latest news stories about VASCULAR BIOGENICS LTD that investors may wish to consider to help them evaluate VBLT as an investment opportunity.
Notable Labs Closes Merger Transaction With VBL Therapeutics- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform (“PPMP”) applied to select and develop |
VBL Therapeutics Announces Results of Annual and Special Shareholder MeetingApproved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and sp |
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingShareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number o |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers that traders will want to watch on Thursday! |
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECMerger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). The definitive merger agreemen |
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateMerger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make good progress towards the closing of o |
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateRecently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvalsMODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “During the first quarter, we made continued progress in the steps we are taking to maximize shareholder value and ar |
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)Vascular Biogenics ( NASDAQ:VBLT ) Full Year 2022 Results Key Financial Results Net loss: US$32.3m (loss widened by... |
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateMODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a corporate update. “I am confident that the recently announced merger with Notable Labs Inc. provides the best path forward and will position the new enterprise to deliver both near and long-term value for shareholders of both companies and patients,” said Prof. Dror Harats, M.D., Chief Executive Office |
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashMODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company. VBL intends to include the proceeds in the Agreement and Plan of Merger entered into with Notable Labs Inc., announced on February 23, 2023. “We are pleased to announce the clo |